Perrigo plummets on plans to shed prescriptions unit
August 10, 2018
Pharmaceuticals | Dublin, Ireland
Pharmaceutical manufacturer Perrigo has announced plans to separate its prescription business following a strategic portfolio review, despite reported struggles to find a buyer. The move is expected to allow Perrigo to focus on its platform of generic pharmaceutical products and expand its consumer business. Shares of Perrigo (NYSE: PRGO) plunged nearly 11% Thursday.